Insights
Not AI news. Not vendor hype. Practical perspectives from working inside complex, compliance-driven workflows every day.
Every retail and CPG company is chasing AI-driven demand forecasting and supply chain orchestration. Almost none of them are asking the right question first: who actually owns the decision the AI is informing?
Everyone's chasing AI transformation. The companies actually seeing returns are targeting something much smaller — the dead time between steps. Here's what that looks like in practice.
FDA's evolving AI/ML SaMD framework isn't a checklist you complete at launch. It's a continuous obligation — and most mid-market device companies aren't built for that.
Every 2026 survey shows retail and CPG leaders bullish on AI. The production reality is far messier — and mid-market operators are the ones absorbing the gap.
The FDA is being pushed to apply clinical laboratory validation standards to AI in medical devices. If you're building AI workflows in this space, that changes the math on what 'ready to deploy' actually means.
MIT research says 95% of enterprise AI projects don't deliver ROI. In regulated industries, the number feels even higher — and the reason isn't the technology.
Every workflow automation vendor is pitching AI-powered efficiency in 2026. Here's why picking the platform before solving the governance problem is how regulated-industry companies end up with a very expensive mess.
Everyone's talking about the 95% failure rate for enterprise AI. But for mid-market operators in regulated industries, the failure mode looks very different — and so does the fix.
Mid-market manufacturers keep buying enterprise AI tools and watching them stall at the integration layer. The problem isn't the algorithm — it's everything the algorithm has to talk to.
The medical device companies getting buried by FDA's evolving AI framework aren't failing on regulatory knowledge — they're failing because they bolted compliance onto a workflow that was never built to carry it.
Everyone in financial services is talking about converging their AI into one unified architecture. Most of them are about to make the same expensive mistake.
Most medical device companies are treating FDA's new AI requirements as a regulatory checkbox. That's exactly why they'll fail. Here's what the framework actually demands — and what it means for how you build.
Manufacturers are pouring money into AI pilots while their scheduling runs on spreadsheets and tribal knowledge. The use cases with the fastest payback aren't the flashy ones.
Everyone's automating invoice coding. Almost nobody is building the compliance scaffolding that makes it stick. Here's the gap mid-market CFOs keep falling into.
Everyone's talking about AI-driven inventory automation. Most mid-market operators are still running on spreadsheets and gut feel. Here's the gap — and how to close it without blowing up your ops.
The FDA's finalizing AI guidance that demands explainability, transparency, and real-world monitoring — and most mid-market device makers aren't remotely ready. Here's what that actually means for your workflows.
MIT found that 95% of enterprise AI pilots deliver zero measurable ROI. For companies in medical device, financial services, or manufacturing, the failure rate isn't just a budget problem — it's a compliance and operational risk.
Manufacturers are moving AI out of the pilot lab and into operations. That's the good news. The hard part — integration, compliance, and change control — is just getting started.
Mid-market manufacturers keep buying AI tools and getting marginal results. The problem isn't the tools — it's that nobody connected them to anything that matters.
Most financial services firms are building AI governance programs that look good on paper and collapse under operational weight. Here's what actually works.
FDA easing oversight on lower-risk AI devices sounds like good news. For mid-market manufacturers, it's actually a trap if you haven't built the right internal scaffolding first.
FDA and EU regulators are locking in AI oversight frameworks for 2026. Most mid-market medical device companies aren't close to ready — and the gap isn't technical, it's operational.
The FDA's 2025 draft guidance on AI-enabled devices buried a major compliance shift inside a document that doesn't even say 'human factors' in the title. Here's what it actually means for your validation strategy.
The FDA just drew clearer lines around AI in medical devices. For mid-market operators, this isn't a compliance headache — it's a forcing function that separates serious AI programs from expensive experiments.
New posts go out when they're ready — no filler, no cadence for cadence's sake.
Get in Touch